Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1982-1983, 2005; 10.1373/clinchem.2005.053124
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orlandi, E.
Right arrow Articles by Swaminathan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orlandi, E.
Right arrow Articles by Swaminathan, R.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Oak Ridge Conference
(Clinical Chemistry. 2005;51:1982-1983.)
© 2005 American Association for Clinical Chemistry, Inc.

Abstracts of Oak Ridge Posters

Factors Affecting Circulating mRNA for Nephrin

Emanuela Orlandi1, Asif Butt1, David Goldsmith2 and R. Swaminathan1,a

Departments of1 Chemical Pathology and 2 Nephrology, Guy’s & St. Thomas’ Hospital, London, United Kingdom;

aaddress correspondence to this author at: Department of Chemical Pathology, 5th Floor, North Wing, St. Thomas’ Hospital, London SE1 7EH, UK; fax 44-207-9284226, e-mail r.swaminathan@kcl.ac.uk)

The first 20% of the full text of this article appears below.

Kidney disease affects more than 20 million individuals in the United States alone. Although the causes of kidney failure are diverse, the glomerular filtration barrier is often the target of injury. Identification of the type of disease is important for targeting therapy. One area of particular interest is the ability to predict which patients with nephrotic syndrome might respond to steroids or cytotoxic therapies and which will not (1). Often this depends on renal biopsy, an invasive procedure with some risk of complications. A noninvasive test to determine the type of renal disease would be advantageous.

During the past decade, nucleic acids have been detected in the circulation, and measurements of tissue-specific DNA and mRNA offer enormous potential for diagnosis and prognosis (2). Increased amounts of nucleic acids have been reported in disease, including lung cancer (3), thyroid cancer (4)(5), stroke(6), and trauma (7). We have recently shown that measurement of total DNA in plasma is a good prognostic marker of outcome in critically ill patients (8). In another study we observed that mRNA for rhodopsin is increased in diabetic retinopathy, and it may be a useful and inexpensive way to detect and monitor diabetic patients for retinopathy (9).

Nephrin, a transmembrane protein with a large extracellular portion including 8 immunoglobulin-like domains, is expressed by visceral epithelial cells (podocytes) in the slit diaphragm of the glomerulus (10). A product of the NPHS1 gene located on chromosome . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Eur J EndocrinolHome page
G. Wang, F. M.-M. Lai, K.-B. Lai, K.-M. Chow, B. C.-H. Kwan, P. K.-T. Li, and C.-C. Szeto
Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker
Eur. J. Endocrinol., March 1, 2008; 158(3): 317 - 322.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.